A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours

Recruiting now · Phase 1/Phase 2

Conditions studied: Advanced Solid Tumor

In brief

The purpose of this study is to determine the appropriate dosage, safety and effectiveness of a new study drug IPN01195 in adults with advanced solid tumours. The participants in this study will have advanced solid tumours. 'Advanced solid tumours' refers to cancers that can occur in several places, including cancers in organs or tissues that have spread from their original site to nearby tissues or other parts of the body.

Key facts

Study ID: NCT06833008
Run by: Ipsen
People needed: 85
Starts: 2025-03-14
Expected to finish: 2028-10-03
Last updated by the study team: 2026-07-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Participants must be ≥18 years of age or the country's legal age of majority if the legal age is more than 18 years at the time of signing the informed consent.
Participants with histologically confirmed metastatic solid tumour for whom no suitable alternative standard therapy exists.
Participants must bear tumours harbouring selected classes of genetic alterations of MAPK pathway based on an analytically validated assay performed by an accredited laboratory.
Part A: Participants must consent to the use of archival tumour tissue or, if not available, collection of fresh tumour biopsy at screening, for central confirmation of mutation status.
Part B: Participants must consent to the use of archival tumour tissue or, if not available, collection of fresh tumour biopsy at screening, for MAPK genomic testing to confirm eligibility.
Participants must have measurable disease per Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1
Eastern Cooperative Oncology Group (ECOG)/performance status (PS) of 0 or 1
Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

You may not qualify if…

Gastrointestinal conditions that could impair absorption of IPN01195 (specific cases e.g. remote history of gastrointestinal surgery, may be enrolled after discussion with the medical monitor)
Any evidence of severe active infection or inflammatory condition.
Non-adequate cardiac function
Known psychiatric or substance abuse disorder, or any other cognitive disorder per the opinion of the investigator that would interfere with the participant's ability to cooperate with the requirements of the study.
Underlying medical conditions that, in the investigator's or sponsor's opinion, will obscure the interpretation of toxicity determination or AEs.
Known second malignancy either progressing or requiring active treatment within the last 2 years prior to first dose of the study intervention.
Active brain metastases or leptomeningeal
Current enrolment or past participation in any other clinical studies involving an investigational study treatment within the last 28 days
Live vaccine(s) within 28 days prior to first dose of the study intervention or plan to receive such vaccines during the study.
Concurrent treatment with any other anti-cancer therapy (including radiotherapy or investigational agents).
Washout period of less than 28 days prior anti-cancer therapy (including chemotherapy, targeted agents, radiotherapy). If the participant was treated with an agent having a short half-life, washout can be <28 days but not shorter than 5 times the half-life.
Condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalents) or other immunosuppressive medications within 2 weeks prior to first dose of the study intervention.
Non-adequate bone marrow function
Non-adequate renal function
Non-adequate hepatic function
Known human immunodeficiency virus (HIV) infection. HIV testing will be performed in any countries where mandatory per local requirements.
Known uncontrolled or untreated hepatitis infection.
(a) Known uncontrolled hepatitis B virus (HBV) infection.
(b) Known untreated current hepatitis C virus (HCV) infection.
Sensitivity to IPN01195 or any of its components.

Where it is running

M.D. Anderson Center Madrid — Madrid, Spain (enrolling)
Sarah Cannon Research Institute (SCRI) - Nashville — Nashville, Tennessee, United States (enrolling)
Mary Crowley Cancer Research Centers - Medical City Hospital - Dallas — Dallas, Texas, United States (enrolling)
START Mountan Region — West Valley City, Utah, United States (enrolling)
Virginia Cancer Specialist- Fairfax — Fairfax, Virginia, United States (enrolling)
START Mid-West — Grand Rapids, Michigan, United States (enrolling)
Paris Saint-Louis — Paris, France (enrolling)
IGR-Villejuif — Villejuif, France (enrolling)
Istituto Nazionale dei Tumori — Milan, Italy (enrolling)
Istituto Nazionale Tumori IRCCS - Fondazione Pascale — Naples, Italy (enrolling)
Val D'Hebron — Barcelona, Spain (enrolling)
Hospital Universitario Quirónsalud Madrid — Madrid, Spain (enrolling)
Centre Léon Bérard - Lyon — Lyon, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.